文献

J-GLOBAL ID：201202266243306911   整理番号：12A0927619

α₅β₁を標的化する一連の非ペプチドRGDインテグリンアンタゴニストの構造-活性相関:パート1

Structure-activity relationship of a series of non peptidic RGD integrin antagonists targeting α₅β₁: Part 1

著者 (21件)： DELOUVRIE Benedicte (AstraZeneca, Centre de Recherches, Z.I. La Pompelle, B.P. 1050, Chemin de Vrilly, 51689 Reims, Cedex 2, FRA) ,  AL-KADHIMI Katherine (AstraZeneca Pharmaceuticals, Alderley Park, Macclesfield, Cheshire SK10 4TG, GBR) ,  ARNOULD Jean-claude (AstraZeneca, Centre de Recherches, Z.I. La Pompelle, B.P. 1050, Chemin de Vrilly, 51689 Reims, Cedex 2, FRA) ,  BARRY Simon T. (AstraZeneca Pharmaceuticals, Alderley Park, Macclesfield, Cheshire SK10 4TG, GBR) ,  CROSS Darren A.E. (AstraZeneca Pharmaceuticals, Alderley Park, Macclesfield, Cheshire SK10 4TG, GBR) ,  DIDELOT Myriam (AstraZeneca, Centre de Recherches, Z.I. La Pompelle, B.P. 1050, Chemin de Vrilly, 51689 Reims, Cedex 2, FRA) ,  GAVINE Paul R. (AstraZeneca R&D, Innovation Center China, Shanghai 201203, CHN) ,  GERMAIN Herve (AstraZeneca, Centre de Recherches, Z.I. La Pompelle, B.P. 1050, Chemin de Vrilly, 51689 Reims, Cedex 2, FRA) ,  HARRIS Craig S. (AstraZeneca, Centre de Recherches, Z.I. La Pompelle, B.P. 1050, Chemin de Vrilly, 51689 Reims, Cedex 2, FRA) ,  HUGHES Adina M. (AstraZeneca Pharmaceuticals, Alderley Park, Macclesfield, Cheshire SK10 4TG, GBR) ,  JUDE David A. (AstraZeneca Pharmaceuticals, Alderley Park, Macclesfield, Cheshire SK10 4TG, GBR) ,  KENDREW Jane (AstraZeneca Pharmaceuticals, Alderley Park, Macclesfield, Cheshire SK10 4TG, GBR) ,  LAMBERT-VAN DER BREMPT C (AstraZeneca, Centre de Recherches, Z.I. La Pompelle, B.P. 1050, Chemin de Vrilly, 51689 Reims, Cedex 2, FRA) ,  LOHMANN Jean-jacques (AstraZeneca, Centre de Recherches, Z.I. La Pompelle, B.P. 1050, Chemin de Vrilly, 51689 Reims, Cedex 2, FRA) ,  MENARD Morgan (AstraZeneca, Centre de Recherches, Z.I. La Pompelle, B.P. 1050, Chemin de Vrilly, 51689 Reims, Cedex 2, FRA) ,  MORTLOCK Andrew A. (AstraZeneca Pharmaceuticals, Alderley Park, Macclesfield, Cheshire SK10 4TG, GBR) ,  PASS Martin (AstraZeneca Pharmaceuticals, Alderley Park, Macclesfield, Cheshire SK10 4TG, GBR) ,  ROONEY Claire (AstraZeneca Pharmaceuticals, Alderley Park, Macclesfield, Cheshire SK10 4TG, GBR) ,  VAUTIER Michel (AstraZeneca, Centre de Recherches, Z.I. La Pompelle, B.P. 1050, Chemin de Vrilly, 51689 Reims, Cedex 2, FRA) ,  VINCENT Jennifer L. (AstraZeneca Pharmaceuticals, Alderley Park, Macclesfield, Cheshire SK10 4TG, GBR) ,  WARIN Nicolas (AstraZeneca, Centre de Recherches, Z.I. La Pompelle, B.P. 1050, Chemin de Vrilly, 51689 Reims, Cedex 2, FRA)
資料名： Bioorganic & Medicinal Chemistry Letters  (Bioorganic & Medicinal Chemistry Letters)
巻： 22  号： 12  ページ： 4111-4116  発行年： 2012年06月15日 
JST資料番号： W0248A  ISSN： 0960-894X  資料種別： 逐次刊行物 (A)
発行国： オランダ (NLD)  言語： 英語 (EN)

タイトルに関連する用語 (4件)： 標的化 ,  ペプチド ,  構造-活性相関 ,  パート